Markets:

Overview

News

Currencies

International

Treasuries

Rezolute, Inc. - Common Stock (NV) (NQ:RZLT)

2.345 -0.005 (-0.21%)

Streaming Delayed Price Updated: 3:38 PM EST, Jan 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Rezolute, Inc. - Common Stock (NV)

< Previous 1 2 3 4 5 6 Next >

CommScope Holding And 2 Other Stocks Under $3 Insiders Are Buying ↗

April 01, 2024

The Dow Jones index closed higher by around 0.1% on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...

Via Benzinga

Topics Stocks

3 Stocks Insiders Are Buying That Analysts Love

March 26, 2024

Insiders are buying these stocks that analysts view as undervalued. Each has a potential catalyst in the works, and its shares could advance triple digits.

Via MarketBeat

$17M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying ↗

March 20, 2024

The Dow Jones index closed higher by over 300 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...

Via Benzinga

Topics Stocks

$1.5M Bet On This Penny Stock? Check Out These 4 Stocks Under $5 Insiders Are Aggressively Buying ↗

March 11, 2024

The Dow Jones index closed lower by around 0.2% on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...

Via Benzinga

Topics Stocks

Analyst Expectations for Rezolute's Future ↗

November 14, 2023

Via Benzinga

Expert Ratings for Rezolute ↗

September 18, 2023

Via Benzinga

What 4 Analyst Ratings Have To Say About Rezolute ↗

June 28, 2023

Via Benzinga

Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)

March 06, 2024

Potential to more than double the addressable patient population living with hypoglycemia resulting from insulin receptor over-activation (tumor hyperinsulinism)

From Rezolute, Inc.

Via GlobeNewswire

Lumen Technologies And 3 Other Stocks Under $3 Insiders Are Buying ↗

February 28, 2024

The Dow Jones index closed lower by around 100 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...

Via Benzinga

Topics Stocks

Charles & Colvard And 3 Other Stocks Under $2 Insiders Are Buying ↗

February 22, 2024

The Dow Jones index closed higher by around 0.1% on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...

Via Benzinga

Topics Stocks

Rezolute And 3 Other Penny Stocks Insiders Are Buying ↗

February 21, 2024

The Dow Jones index closed lower by more than 60 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...

Via Benzinga

Topics Stocks

Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update

February 13, 2024

From Rezolute, Inc.

Via GlobeNewswire

Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer

January 24, 2024

From Rezolute, Inc.

Via GlobeNewswire

Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

January 23, 2024

From Rezolute, Inc.

Via GlobeNewswire

Why Aclarion Shares Are Trading Higher By Around 53%; Here Are 20 Stocks Moving Premarket ↗

December 20, 2023

Shares of Aclarion, Inc. (NASDAQ: ACON) shares rose sharply in pre-market trading after the company was granted U.S. patent #11844601 for "MR SPECTROSCOPY SYSTEM FOR DIAGNOSING PAINFUL AND NON-PAINFUL...

Via Benzinga

Topics Intellectual Property

Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)

December 13, 2023

Plans to report topline data mid-second quarter 2024

From Rezolute, Inc.

Via GlobeNewswire

Stonegate Healthcare Partners Announces Black Friday Biotech Special Report For an "XBI-MAS"

November 24, 2023

Dallas, Texas--(Newsfile Corp. - November 24, 2023) - Stonegate Healthcare Partners highlights a unique opportunity in its report, "Black Friday...

Via Newsfile

Rezolute to Participate in BTIG’s 3rd Annual Ophthalmology Day

November 17, 2023

From Rezolute, Inc.

Via GlobeNewswire

Rezolute Reports First Quarter Fiscal 2024 Results

November 13, 2023

From Rezolute, Inc.

Via GlobeNewswire

Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism

October 17, 2023

PRIME eligibility granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital hyperinsulinism

From Rezolute, Inc.

Via GlobeNewswire

Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism

October 11, 2023

From Rezolute, Inc.

Via GlobeNewswire

Stocks That Hit 52-Week Lows On Monday ↗

October 02, 2023

On Monday, 369 companies set new 52-week lows.

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

September 15, 2023

Via Benzinga

Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress

September 14, 2023

Planning to initiate Phase 3 Study for RZ358 (“sunRIZE study”) in the fourth quarter of 2023

From Rezolute, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

September 08, 2023

Via Benzinga

Rezolute to Participate in Upcoming Investor Conferences in September

September 06, 2023

From Rezolute, Inc.

Via GlobeNewswire

Rezolute And 2 Other Penny Stocks Insiders Are Aggressively Buying ↗

July 07, 2023

The Dow Jones closed lower by over 300 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...

Via Benzinga

Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism

June 27, 2023

From Rezolute, Inc.

Via GlobeNewswire

Stonegate Healthcare Partners Announces Publishing of a Thematic Report - Beyond VEGF: Therapies Revolutionizing Diabetic Eye Disease

June 01, 2023

Dallas, Texas--(Newsfile Corp. - June 1, 2023) - Stonegate Healthcare Partners (SHP), a healthcare...

Via Newsfile

Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress

May 11, 2023

The Company is poised to commence Phase 3 for RZ358 in the third quarter of calendar year 2023

From Rezolute, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.